Abstract
In order to clarify the role of mitomycin (MMC) in the treatment of NSCLC, we performed a systematic review of the literature and qualitatively assessed the selected studies using the ELCWP and Chalmers scales. 5 trials (202 patients) assessed the activity of MMC as single-agent chemotherapy in NSCLC. The overall response rate was 25% (95% Cl 19–31). In 10 randomized phase III trials (1769 patients), we studied the role of MMC in combination therapy. A meta-analysis, based on the available published data, failed to show any survival advantage of the MMC containing regimens (hazard ratio = 0.95; 95% Cl 0.83–1.10). Finally, 4 eligible trials (139 patients) assessed the activity of MMC regimens as salvage therapy, 3 in combination with vindesine and one with cisplatin and vinblastine. The overall response rate for the MMC-vindesine regimen was 10.5% (95% Cl 1.7–19.4). In conclusion, MMC is an active drug for NSCLC but does not improve survival when combined with other active drugs, particularly cisplatin. Its use for salvage therapy appears to be associated with marginal activity only. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J and Comis R (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613
Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D and Ambroz A (1981) A method for assessing the quality of a randomized control trial. Control Clin Trials 2: 31–49
Crino L, Darwish S, Corgna E, Meacci ML, Di Costanzo F, Buzzi F, Fornari G, Santi F, Ballatori E and Luccioli L (1988) Treatment of advanced non-small cell lung cancer (NSCLC): the “Umbria” cooperative study. Semin Oncol 15: 52–55
Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Costanzo F, Buzzi F, Fornari G, Santi E and Ballatori E (1990) A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 26: 52–56
Donnadieu N, Paesmans M and Sculier JP (1991) Chimiothérapie du cancer bronchique non à petites cellules: méta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Respir 8: 197–204
Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J and Fisher W (1986) Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037–1043
Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M and Ogawara M (1991) A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9: 606–613
Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW and Grunberg SM (1993) Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873–878
Gridelli C, Airoma G, Incoronato P, Pepe R, Palazzolo G, Rossi A and Bianco AR (1992) Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 30: 212–214
Israel L, Chahinian P and Depierre A (1975) Response of 65 measurable epidermoid bronchogenic tumors of known spontaneous doubling time to four different chemotherapeutic regimens – strategic deductions. Medical and Pediatrics Oncology 1: 83–93
Kris MG, Gralla RJ, Kelsen DP, Casper ES, Burke MT, Fiore JJ, Cibas IR and Heelan RT (1985) Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest 87: 368–372
Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R and Greco FA (1990) Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 8: 886–891
Marino P, Pampallona S, Preatoni A, Cantoni A and Invernizzi F (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 106: 861–865
Marino P, Preatoni A, Cantoni A and Buccheri G (1995) Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 13: 1–12
Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P and Sculier JP (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30: 23–36
Masutani M, Akusawa H, Kadota A, Ohchi Y, Takahashi N, Tanigawa S, Koya Y and Horie T (1996) A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology 1: 49–54
Meert AP, Berghamans T, Branle F, Lemaitre F, Mascaux C, Rubesova E, Vermylen P, Paesmans M and Sculier JP (1999) Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res 19: 4379–4390
Mylonakis N, Tsavaris N, Bacoyiannis C, Karvounis N, Kakolyris S, Karabelis A, Beer M and Kosmidis P (1992) A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer. Ann Oncol 3: 127–130
Niell HB, Griffin JP, Hunter RF, Meredith CA and Somes G (1989) Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Med Pediatr Oncol 17: 69–75
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909
Ruckdeschel JC, Mehta CR, Salazar OM, Cohen M, Vogl S, Koons LS and Lerner H (1981) Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II. Cancer Treat Rep 65: 965–972
Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile RJ and Crooke ST (1978) Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62: 163–165
Sculier JP, Klastersky J, Dumont JP, Vandermoten G, Rocmans P, Libert P, Ravez P, Becquart D, Mommen P and Dalesio O (1986) Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: a pilot study by the Lung Cancer Working Party (Belgium). Cancer Treat Rep 70: 773–775
Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F and Saijo N (1991) A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 27: 571–575
Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RFJ, Kardinal CG and Maksymiuk AW (1992a) A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 70: 2281–2287
Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RF Jr, Kardinal CG and Maksymiuk AW (1992b) A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 70: 2281–2287
Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CAJ, Taylor SA and Livingston RB (1991) A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 9: 1157–1162
Author information
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sculier, J., Ghisdal, L., Berghmans, T. et al. The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer 84, 1150–1155 (2001). https://doi.org/10.1054/bjoc.2001.1742
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1742
Keywords
This article is cited by
-
Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages
Journal of Experimental & Clinical Cancer Research (2018)
-
Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer
Pharmaceutical Research (2018)
-
The clinicopathological significance and potential drug target of E-cadherin in NSCLC
Tumor Biology (2015)
-
Canonical and new generation anticancer drugs also target energy metabolism
Archives of Toxicology (2014)
-
Histology as a Potential Clinical Predictor of Outcome in Advanced Non-Small-Cell Lung Cancer Treated with Vinorelbine and Mitomycin Combination Chemotherapy
Lung (2013)